iOWH032

Small molecule targets CFTR via inhibition

today NCT04150250 · Ph 2 NCT01823939 · Ph 1

201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT01823939	May → Nov 2013	cholera, diarrheal disease	PATH	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT04150250	Nov 2019 → Jul 2020	cholera	PATH	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT02111304 Comparator	Jun 2014 → Jan 2016	secretory diarrhea	PATH	Withdrawn	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	iOWH032	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02111304 ↗ 2 NCT04150250 ↗ NCT01823939 ↗
Action	Inhibit	“inhibitor of the cystic fibrosis transmembrane conductance regulator chloride channel” PMID 34793441 ↗ Nov 2021
Modality	Small molecule	“synthetic small molecule inhibitor” PMID 34793441 ↗ Nov 2021
Route	Oral	“Active treatment will consist of an oral tablet containing 300 mg of iOWH032.” NCT01823939 ↗
Target	CFTR	“inhibitor of the cystic fibrosis transmembrane conductance regulator chloride channel” PMID 34793441 ↗ Nov 2021